Pityriasis rosea is a skin condition that causes a Christmas tree rash. It starts with one patch, known as the mother patch, and branches out with smaller daughter patches on other parts of the body.
Although the rash will go away on its own with time, some people turn to medication, topical treatments, and dietary changes in an attempt to improve their symptoms (1, 2).
This article explores whether any diet, supplements, or other treatments can help treat pityriasis rosea.
Pityriasis rosea is a skin condition. It causes scaly, oval-shaped rashes that begin on the stomach, back, or chest and branch out onto the neck, arms, and legs (1, 2).
Its considered a self-limiting condition, meaning that it goes away on its own. It typically lasts 68 weeks, though it can last longer in some people (1, 2).
In most cases, the rash does not return once it has gone away, although one small study estimated that around 25% of people will experience recurrence (3).
Some, but not all, people with pityriasis rosea experience mild itching. Other symptoms of the condition are fatigue, nausea, headaches, fever, and sore throat. These symptoms can occur before or at the same time as the rash (2).
Sometimes, pityriasis rosea is mistaken for other skin conditions such as psoriasis, eczema, or ringworm. Your doctor may order blood tests to rule out other conditions before confirming a pityriasis rosea diagnosis.
The cause of pityriasis rosea is not known. Some speculate that it could be associated with a viral infection because it has been shown to spread through communities (2).
Anyone can get pityriasis rosea, but its most common between the ages of 10 and 35 and in those who are pregnant (2, 4).
Pityriasis rosea in pregnancy may be linked to miscarriage, especially during the first 15 weeks, although this correlation is not confirmed (1).
Because the rash goes away on its own with time, treatment is typically focused on symptom relief. Medical treatment can include antihistamines, topical steroids, and light therapy, all of which aim to reduce the intensity of itching (1).
Pityriasis rosea is a skin condition associated with a rash that can be itchy. The rash goes away on its own, often after 68 weeks, and treatment typically focuses on symptom relief.
No research directly supports the idea that dietary changes can help manage pityriasis rosea.
Still, some people believe that eating an anti-inflammatory diet might improve itching. An anti-inflammatory diet is high in foods that provide antioxidants, beneficial compounds that help prevent oxidative stress in your body (5).
Because pityriasis rosea is thought to be associated with increased oxidative stress, eating a diet high in antioxidants theoretically makes sense. However, there is currently no research supporting this idea (5).
Similarly, some people believe that the Autoimmune Protocol a diet that aims to lower inflammation could reduce pityriasis rosea symptoms (6).
In theory, a diet that decreases inflammation in your body might help manage the itching associated with the condition. However, no research supports this idea.
Current research doesnt suggest that any specific dietary changes can treat pityriasis rosea. Still, some people theorize that anti-inflammatory or antioxidant-rich diets might help relieve itching.
Pityriasis rosea usually goes away on its own, without requiring treatment. Still, certain supplements, topical treatments, medications, and lifestyle changes may offer some relief for those who experience irritated, itchy skin.
No strong evidence indicates that any supplements could help treat pityriasis rosea. However, certain supplements may relieve itchy skin in general.
Research suggests that vitamin D may relieve skin itch associated with eczema, a condition that makes skin red and itchy. One study found that taking 1,5001,600 IU of vitamin D per day reduced the severity of the symptoms (7, 8).
Fish oil is another supplement that has been shown to benefit the skin. One study in rats found that a daily fish oil supplement relieved itchiness associated with dry skin (9, 10).
Taking turmeric as a supplement and applying it topically may also help relieve itchy skin thanks to turmerics anti-inflammatory and antioxidant properties (11, 12, 13).
Lastly, animal studies have found that compounds in bilberry may relieve itchy skin (14).
Keep in mind that although these potential anti-itch benefits of vitamin D, fish oil, turmeric, and bilberry are promising, more research in humans is still needed.
Further, these supplements have not been studied specifically in relation to pityriasis rosea. If youre experiencing itchy skin from the rash, its best to talk with your doctor to see if any of these supplements are worth a try.
Certain topical treatments may relieve some of the itching caused by pityriasis rosea.
Hydrocortisone is a cream that reduces your skins immune response to relieve itching, swelling, and redness. However, its not recommended for long-term use, so its a good idea to check with your doctor if youre interested in trying it (15).
Another option is calamine lotion. It contains zinc oxide, an essential mineral that can help with itching. It does so by decreasing the effects of histamine, a compound thats part of your bodys immune response and is associated with symptoms like itching (16).
Applying aloe vera may also cool and calm itchy skin. You can find bottled aloe vera in stores or use the gel from a fresh aloe vera leaf. When looking for aloe vera products, check out the ingredients and choose one that has aloe vera listed first (17).
Interestingly, oatmeal has been found to have antioxidant and anti-inflammatory properties that may soothe irritated skin. Simply add 12 cups of oats to a bath and soak for 1520 minutes. You can also look for lotions containing oatmeal to enjoy its benefits (18, 19).
While these topical remedies may provide some relief, they wont treat the condition. Further, even though theyre generally considered safe, its best to talk with your doctor before trying them, especially if youre pregnant or breastfeeding.
Your doctor may be able to prescribe a stronger topical treatment if none of these over-the-counter options do the trick.
Over-the-counter antihistamines like diphenhydramine (Benadryl) and cetirizine (Zyrtec) can relieve itching by blocking the effects of histamine. Keep in mind, though, that some types may make you sleepy (20, 21).
Acyclovir, a drug often used to treat chickenpox, may also help those with pityriasis rosea. In fact, research has found that it may reduce skin redness, relieve symptoms, and even reduce the duration of rash (22, 23, 24).
A type of anti-inflammatory medications known as corticosteroids may also improve symptoms, although they are recommended only for severe or lingering cases of the condition. One study found that relapse rate was higher in those who were treated with a corticosteroid (25).
Some lifestyle factors may affect your skin, especially if youre dealing with a rash.
Try to avoid hot temperatures, as they can cause sweating, which might irritate your rash. Hot baths and showers and perfume-containing soaps and lotions may also cause irritation.
Because symptoms such as fatigue, nausea, fever, and sore throat can occur before or at the same time as the rash, be sure to get plenty of rest, stay hydrated, and check in with your doctor to make sure youre staying healthy.
Although pityriasis rosea cant be cured, certain medications, topical treatments, supplements, and lifestyle changes may reduce your symptoms.
There is currently no research to suggest that dietary changes can help treat or manage pityriasis rosea.
However, remedies such as antihistamines and topical treatments can help relieve itchy, irritated skin. And avoiding hot temperatures may help you avoid further irritating your skin.
Its best to talk with your doctor to find out which options may work best for you especially if youre pregnant or breastfeeding.
Remember, the rash usually goes away on its own without treatment.
See the rest here:
Pityriasis Rosea and Diet: Is There a Connection? - Healthline
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]